Cancer Treatment Reviews
Volume 29, Issue 5 , Pages 449-452, October 2003

Sequential paclitaxel reduces recurrence and mortality in women with early breast cancer☆☆☆★

The University of Texas, M.D. Anderson Cancer Center, Houston TX, USA

Abstracted from: Henderson C., Berry DA., Demetri GD. et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. Journal of Clinical Oncology 2003;21: 976–983.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Sources of funding: Supported in part by Grant no. CA31946 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD. After completion of the trial, Bristol-Myers Squibb provided a grant for statistical and administrative support.

☆☆ For correspondence: I. Craig Henderson, MD, University of California at San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA 94143. E-mail: craig.henderson@accessoncology.com.

★ Abstract provided by Bazian Ltd., London.

PII: S0305-7372(03)00167-1

doi:10.1016/S0305-7372(03)00167-1

Cancer Treatment Reviews
Volume 29, Issue 5 , Pages 449-452, October 2003

Article Tools